Table 1.

Characterization of SF based on patients' data.

	Age range	Age range at diagnosis	Treatment	DAS28-CRP	SF nucleated cell count (/mm3)	RF	ACPA	Erosion	Other
CTL									SF control from a patient undergoing non-inflammatory rheumatism-related surgery
SpA1	30–35	36-40	MTX		4,900			+	Spondyloarthritis
SpA2	66–70	Undetermined	Flurbiprofen		12,800				Psoriasis
RA1	60–65	50–55	Tocilizumab	5.77	15,200	+	+	+
RA2	70–75	60–65	MTX, abatacept	6.58	8,250	+	+	+
RA3	70–75	70–75	None	5.35	3,400	+	–	–
RA4	26–30	0–5 (Juvenile arthritis)	MTX, etanercept	4.29	15,000	–	–	–
RA5	76–80	40–45	MTX	3.84	4,000	+	–	+
RA6	50–55	30–35	MTX, sulfasalazine, hydroxychloroquine	3.54	35,000	+	+	+
RA7	80–85	60–65	None	4.26	9,500	+	+	+
RA8	60–65	26–30	Prednisolone	3.89	19,400	+	–	–

SF were obtained from eight different RA patients, two SpA patients and one control SF from a non-rheumatologic joint. CTL, control; SpA, spondyloarthritis; RA, rheumatoid arthritis; DAS28-CRP, Disease Activity Score 28 using C-reactive protein; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; MTX, methotrexate.